Jo Ann Baker
Family · Smyrna, DENPI 1023226248
Payments from drug & device makers
Across 119 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$542
- Novo Nordisk$408
- Dexcom, Inc.$235
- Abbott$190
- AbbVie$173
- Amgen$159
- plus $919 from 16 others
What the payments were for
- Food & beverage$2,627100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $542 |
| Novo Nordisk | 24 | $408 |
| Dexcom, Inc. | 14 | $235 |
| Abbott | 10 | $190 |
| AbbVie | 9 | $173 |
| Amgen | 9 | $159 |
| Pfizer | 8 | $143 |
| Ultragenyx Pharmaceutical Inc. | 1 | $125 |
| GSK | 6 | $108 |
| Boehringer Ingelheim | 6 | $99 |
| Lilly USA, LLC | 5 | $97 |
| Shield Therapeutics Inc | 3 | $95 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Astellas Pharma US Inc | 2 | $36 |
| Tactile Systems Technology Inc | 1 | $35 |
| Merck | 2 | $31 |
| Mylan Specialty L.p. | 1 | $25 |
| Exact Sciences | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Bayer | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,627 in reported general payments places this provider in the 80th percentile of 523 family providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 17 | $25,819 |
| OzempicSemaglutide | 16 | $18,708 |
| EliquisApixaban | 13 | $12,126 |
| Rosuvastatin Calcium | 40 | $737 |
| Omeprazole | 30 | $578 |
| Gabapentin | 26 | $578 |
| Atorvastatin Calcium | 47 | $558 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $527 |
| Pantoprazole Sodium | 24 | $502 |
| Levothyroxine Sodium | 28 | $466 |
| Metformin Hcl | 51 | $386 |
| Metoprolol Succinate | 26 | $347 |
| Famotidine | 21 | $292 |
| Amlodipine Besylate | 42 | $268 |
| Quetiapine Fumarate | 12 | $253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $97 | $25,81917 claims |
| Novo NordiskOzempic | $408 | $18,70816 claims |
| PfizerEliquis | $143 | $12,12613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 523 family providers in Delaware.
Other family in Smyrna
- Brandi GreggeMiddletown$110K
- Tracy EstesWilmington$59K
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Abby AllenGeorgetown$43K
- Taylor HodgesLewes$33K
- Jodi KahanWilmington$21K
- Valerie HarrisonBridgeville$15K
- Kathleen GustafsonBear$15K
- Elizabeth Sharp-AsiyoWilmington$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.